INFI - インフィニティ・ファ―マシュ―ティカルズ (Infinity Pharmaceuticals Inc.) インフィニティ・ファ―マシュ―ティカルズ

 INFIのチャート


 INFIの企業情報

symbol INFI
会社名 Infinity Pharmaceuticals Inc (インフィニティ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インフィニティ・ファーマシューティカルズ(Infinity Pharmaceuticals Inc.)は創薬・新薬開発会社。同社の主力製品は同社が血液悪性腫瘍と炎症性疾患において研究しているクラスI ・PI3K- デルタとPI3K- ガンマの強力な経口阻害剤である。同社のretaspimycin塩酸塩(HCl)は熱ショック蛋白質90(Hsp90)の強力な選択的阻害剤である。ホスホイノシチド3 - キナーゼ(PI3K)は中心ノードとして細胞表面受容体から下流の生化学的事象へ信号を伝達する重要な細胞信号伝達蛋白質である。同社のこのプログラムにおける主力開発候補は臨床試験が行われた、血液悪性腫瘍と炎症性疾患を形成するクラスI PI3K-デルタ・ガンマの強力な経口阻害剤IPI-145である。血液悪性腫瘍は血液・骨髄の癌であり、慢性リンパ性白血病(CLL)、ホジキンリンパ腫、非ホジキンリンパ腫(NHL)などの白血病とリンパ腫を含む。   インフィニティ・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。主力製品候補のIPI-145は血液悪性腫瘍と炎症性疾患を対象とする、ホスホイノシチド3-キナ―ゼ(PI3K)のクラスIデルタとガンマアイソフォ―ムの経口阻害剤である。またIPI-443などを参考に、第二のPI3K製品候補、PI3Kデルタとガンマの経口阻害剤を開発。   Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
本社所在地 784 Memorial Drive Cambridge MA 02139 USA
代表者氏名 Adelene Q. Perkins アデリーンQ.パーキンス
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 617-453-1000
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 22人
url www.infi.com
nasdaq_url https://www.nasdaq.com/symbol/infi
adr_tso
EBITDA EBITDA(百万ドル) -32.06800
終値(lastsale) 2.45
時価総額(marketcap) 139283842.6
時価総額 時価総額(百万ドル) 144.96890
売上高 売上高(百万ドル) 6.00000
企業価値(EV) 企業価値(EV)(百万ドル) 95.80390
当期純利益 当期純利益(百万ドル) 43.64100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Infinity Pharmaceuticals Inc. revenues was not reported. Net loss decreased 40% to $16.4M. Lower net loss reflects Other expense decrease from $6.9M (expense) to $0K Other General and administrative decrease of 44% to $5.5M (expense) Stock Based compensation in General and decrease of 46% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.31.

 INFIのテクニカル分析


 INFIのニュース

   Myxoid Round Cell Liposarcoma Drug Market 2020 Emerging Players - Adaptimmune, Recordati SpA, Merck & Co., Inc, Novartis AG, Infinity Pharmaceuticals, Inc., Mirati Therapeutics, Inc  2020/10/01 19:07:55 OpenPR
Myxoid Round Cell Liposarcoma Drug Market Research Report By Therapy (Chemotherapy, Radiation Therapy and Others), Drugs (Trabectedin, Mechlorethamine and Others), Route of Administration (Injectable, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others),
   Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results  2020/07/30 20:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. “We have made important clinical progr
   Thinking about buying stock in Infinity Pharmaceuticals, Qudian Inc, Myomo Inc, Plug Power, or Sunrun Inc?  2020/07/09 13:31:00 PR Newswire
NEW YORK, July 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INFI, QD, MYO, PLUG, and RUN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Will Infinity Pharmaceuticals (INFI) Report Negative Q1 Earnings? What You Should Know  2020/04/28 16:33:07 Zacks Investment Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Why Infinity Pharmaceutical's Stock Is Trading Higher Today  2020/03/25 08:37:00 Benzinga
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares are trading higher on Wednesday, after the company announced the FDA has granted fast track designation …
   Myxoid Round Cell Liposarcoma Drug Market 2020 Emerging Players - Adaptimmune, Recordati SpA, Merck & Co., Inc, Novartis AG, Infinity Pharmaceuticals, Inc., Mirati Therapeutics, Inc  2020/10/01 19:07:55 OpenPR
Myxoid Round Cell Liposarcoma Drug Market Research Report By Therapy (Chemotherapy, Radiation Therapy and Others), Drugs (Trabectedin, Mechlorethamine and Others), Route of Administration (Injectable, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others),
   Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results  2020/07/30 20:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. “We have made important clinical progr
   Thinking about buying stock in Infinity Pharmaceuticals, Qudian Inc, Myomo Inc, Plug Power, or Sunrun Inc?  2020/07/09 13:31:00 PR Newswire
NEW YORK, July 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INFI, QD, MYO, PLUG, and RUN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Will Infinity Pharmaceuticals (INFI) Report Negative Q1 Earnings? What You Should Know  2020/04/28 16:33:07 Zacks Investment Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Why Infinity Pharmaceutical's Stock Is Trading Higher Today  2020/03/25 08:37:00 Benzinga
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares are trading higher on Wednesday, after the company announced the FDA has granted fast track designation …
   Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results  2020/07/30 20:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. “We have made important clinical progr
   Thinking about buying stock in Infinity Pharmaceuticals, Qudian Inc, Myomo Inc, Plug Power, or Sunrun Inc?  2020/07/09 13:31:00 PR Newswire
NEW YORK, July 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INFI, QD, MYO, PLUG, and RUN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Will Infinity Pharmaceuticals (INFI) Report Negative Q1 Earnings? What You Should Know  2020/04/28 16:33:07 Zacks Investment Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Why Infinity Pharmaceutical's Stock Is Trading Higher Today  2020/03/25 08:37:00 Benzinga
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares are trading higher on Wednesday, after the company announced the FDA has granted fast track designation …
   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インフィニティ・ファ―マシュ―ティカルズ INFI Infinity Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)